GenVec is a biotechnology company pioneering the development and commercialization of gene therapy products for major disease markets. GenVec's lead product, the BIOPASS system, is designed to treat severe heart disease by causing the growth of new blood vessels near the heart. BIOPASS is being developed through a major strategic alliance with Parke-Davis Research, a division of the Warner-Lambert Company.

Founders: Cynthia L. Collins